SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas quarterly results are the main focus: earnings and revenue narrowly beat expectations, but traders are debating the sharp declines in operating income and free cash flow as shares move higher. Some attribute the bullish reaction to SpaceX merger speculation, though a deal remains uncertain.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas quarterly results are driving attention: traders are cheering strong revenue and ad growth and an upbeat outlook, while many attribute the reported earnings shortfall to a one-time legal charge. Debate centers on rising AI spending, cash burn and planned nonvoting share issuancebulls see investment in future AI growth, while bears worry about returns and dilution.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Researchs earnings report is driving attention: traders cite a quarterly beat, but shares sold off as investors weigh whether the outlook and guidance can justify high expectations. Some see the pullback as a buying opportunity, while others view it as a sell-the-news reaction and remain cautious about valuation and peak-demand risks.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBMs quarterly results beat revenue and earnings expectations, and the company raised its full-year free-cash-flow outlook, prompting a positive share reaction. Traders welcomed the stronger cash-flow guidance but debated weak mainframe sales, softer consulting, and narrower-than-expected margins.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is drawing attention amid continued share-price weakness and concerns about slowing core Celsius sales, Nielsen trends, and margin pressure; traders are watching upcoming earnings for evidence of a turnaround. Bulls point to Alani Nu growth and insider purchases, while talk of a Pepsi buyout remains speculation.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is drawing attention as an AI data-center power play after comments that electricity and cooling are bottlenecks to AI expansion, reinforced by fuel-cell project news and anticipation of Q3 results. Bulls see demand supporting growth, while skeptics point to the premium valuation and warn that earnings could bring more volatility or a sell-the-news reaction.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp

Discussion centers on reports that the Navy halted further purchases of BlackSeas GARC drone boats, prompting a steep selloff in AVEX. Bears view the loss as a serious blow to the acquisition and contract outlook, while bulls argue GARC is only one part of the business and point to other Navy programs and potential contract remedies.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

SLV is drawing attention amid a sharp, volatile pullback in silver, which traders often attribute to rising yields and a stronger dollar. Bears see further downside after the metals earlier surge, while long-term holders are buying dips and some traders blame paper-market shorting, citing supply concerns and industrial demand.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas investor presentation and the pending Phase 3 HLP003 readout for major depressive disorder, expected in Q4 2026. Traders are split between optimism about the programs earlier results and concern about whether efficacy will hold up in Phase 3, with financing needs and volatile price action adding to the debate.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is centered on the full Phase 3 INTerpath-001 melanoma vaccine data at ESMO, with traders focused on the magnitude and durability of benefit after the trial met key endpoints. Bulls see the cancer-vaccine pipeline as a major growth opportunity and point to squeeze momentum, while skeptics argue the run-up has outrun fundamentals and could reverse on a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability

Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.read more...

Children's Hospital Formulary Wins Lift Liquid Blood Pressure Drug Maker

For children who cannot swallow tablets or need individualized doses, the pharmacy often becomes the final step in manufacturing their medicine. Ready-to-use liquid formulations can remove that preparation burden, but hospital formulary access is an important step toward getting them into routine care.Shares of Scienture Holdings, Inc. (NASDAQ: SCNX) are climbing Friday after the company announced that Arbli&#8482;, its losartan potassium oral suspension, has been added to the formularies of three leading U.S. pediatric academic medical centers and hospitals. The institutions specialize in ...

SCIENTURE Scores Major Pediatric Breakthrough as Arbli Lands at 3 Top U.S. Hospitals

SCIENTURE (NASDAQ:SCNX) is giving investors a fresh commercial catalyst as its FDA-approved Arbli oral suspension wins formulary placement at three leading U.S. pediatric academic medical centers and hospitals. The additions expand the product’s institutional footprint at a critical point in its rollout, while the company says wholesale orders have continued to increase sequentially. For a specialty pharmaceutical company focused on products addressing specific patient and healthcare-system needs, the latest formulary wins provide a tangible measure of expanding access for Arbli.

Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened

Scienture Holdings shares tumble 19% after hours following a newly announced 1-for-25 reverse stock split.read more...

Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why

Scienture Holdings shares jumped 23.54% overnight after the company completed manufacturing inventory for the commercial launch of REZENOPY.read more...

Scienture Holdings Stock Climbs 31% After GPO Agreements For REZENOPY Naloxone Spray

(RTTNews) - Shares of Scienture Holdings, Inc. (SCNX) are moving up about 31 percent on Wednesday morning trading after the company formalized multiple commercial Group Purchasing Organization...

Why Is Scienture Stock Rising Today?

Equity

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Commack, NY.

Scienture Holdings Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Scienture has commenced selling Arbli, the first FDA-approved ready-to-use liquid losartan formulation.</li><li>The U.S. losartan market is worth about $256 million annually, offering strong growth potential for Arbli.</li><li>Scienture secured key GPO agreements to expand Arbli’s availability to over 2,500 healthcare facilities nationwide.</li></ul>Scienture Holdings Inc. (SCNX) on Thursday announced the launch of commercial sales for its new product, Arbli (losartan potassium) Oral Suspension, 10 mg/mL.Arbli is the first FDA-approved, ready-to-use oral suspension of losartan potassium, offering patients who require alternatives to pills a safe and consistent treatment option.&nbsp;With the U.S. losartan market generating around $256 million annually and more than 71 million prescriptions written each year, according to IQVIA data, Scienture sees a strong potential for this new product.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of Scienture Holdings surged by more than 122% by Thursday noon. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img style="aspect-ratio:938/107;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_23_114143_png_e27a7261e9.webp" alt="SCNX’s Sentiment Meter and Message Volume as of 11:25 a.m. ET on Oct. 23, 2025 | Source: Stocktwits" width="938" height="107"><figcaption>SCNX’s Sentiment Meter and Message Volume as of 11:25 a.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said the company’s valuation might reach billions if the product is expanded globally.&nbsp;<stembedurl>https://stocktwits.com/jreddyN/message/633437362</stembedurl><h2 class="st-heading-2">Arbli’s Importance</h2>Arbli is a unique liquid form of losartan, a common medication for high blood pressure. It doesn’t need compounding, offers a smaller dosing volume, and has a long shelf life at room temperature. Arbli is approved to treat hypertension in patients over six years old, to lower stroke risk in those with hypertension and heart enlargement, and manage diabetic kidney disease in certain type 2 diabetes patients.To support Arbli’s market entry, Scienture has secured Pharmacy Benefit Manager-led Group Purchasing Organization (PBM-Led GPO) agreements to broaden commercial coverage and formulary inclusion. Scienture has also finalized contracts with multiple commercial GPOs, allowing Arbli to reach over 2,500 healthcare institutions nationwide.&nbsp;Scienture’s stock has lost over 79% in 2025 and over 82% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/datavault-ai-to-boost-growth-with-new-headquarters-quantum-centers/cLG4mQdR3rQ">Datavault AI To Boost Growth With New Headquarters, Quantum Centers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Scienture has commenced selling Arbli, the first FDA-approved ready-to-use liquid losartan formulation.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.91
Prev Close	$3.05
Open	$3.04
Dividend Yield	0.00%
50-Day Moving Average	$7.66
Beta	1.52
Avg. Volume	60,864.96
PE Ratio	-0.07

52-Week High	$65.00
52-Week Low	$2.81
Market Capitalization	$5.01M
EPS (Annual)	-$67.62
Price to Book	0.08
Revenue Per Employee	$47,956.56

Feed

News

Sentiment

Fundamentals

Info

SCNX Fundamentals